Doubtful - I think the market has pretty much written off migalistat, but it is as much the company's fault with how they have dealt with the program. If you read between the lines of the 6 month results, it was clear that the drug was effective - as the post-hoc analysis shows - but the trial design is flawed because of how they are measuring "response" - it picks up too many placebo responders because of measurement noise of those with mild disease. In any event, when they made the decision not to file and NDA until the replacement study is done next year, the market said forget it. Perhaps they will try to resurrect it when the 12 month results of this current trial are out, but I doubt it? A ton of long term value here - they could have paid for it cheaply if they had run the migalistat trial properly, but with the share price so low and the other programs not being completed until 2016+, it will take a lot of patience and potentially dilution?